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measuring the D-shaped annulus as compared to cardiac CT.
METHODS Patients being considered for TMVI with moderate-severe
mitral regurgitation between 2012 and 2014 at St Paul’s Hospital,
Vancouver, B.C. were included in this retrospective study. Patients
who did not have both 3D-TEE and cardiac CT were excluded. Pre-
existing Philips Q-Laboratory mitral valve quantiﬁcation software was
used and our group created a modiﬁed protocol to speciﬁcally mea-
sure the D-shaped annulus. A single observer analyzed all cases and a
second observer analyzed 15 cases for inter-observer variability. A
third observer unfamiliar with the study, followed the protocol and
analyzed 15 cases. The relationship between 3D-TEE and cardiac CT
measured annular dimensions was evaluated using linear regression
analysis Spearmans Rho non-parametric correlation coefﬁcient.
Bland-Altman analysis was performed to assess agreement between
the two imaging modalities. Inter- and intra-observer agreement was
quantiﬁed with intraclass correlation coefﬁcient.
RESULTS Forty-one patients were included in the study: age 77þ14
years; 71% males (n¼29); mitral regurgitation etiology functional in
54% (n¼22) and myxomatous in 46% (n¼19); severe mitral regurgita-
tion in 88% (n¼36). The correlations between cardiac CT and 3D-TEE
mitral annular measurements were as follows: area (r¼0.84,
p<0.0001); circumference (r¼0.82, p<0.0001); TT distance (r¼0.68,
p<0.0001) and SL distance (r¼0.69, p<0.0001). The Bland-Altman
analysis showed good agreement of all parameters with the exception
of circumference: mean bias 3DTEE-CT, area ¼ -0.181.8cm (p¼0.54),
TT distance ¼ 1.13.4mm (p¼0.05), SL distance ¼ 0.673.6mm
(p¼0.23), and circumference ¼ 811mm (p<0.001). There was excel-
lent intra- and inter-observer agreement with intra-class correlation
coefﬁcients > 0.90 for all annular parameters.
CONCLUSIONS This study demonstrates that 3D echocardiographic
assessment of the D-shaped mitral annulus is comparable to cardiac
CT. The use of pre-existing mitral valve quantiﬁcation software with a
standardized protocol allows an observer to provide an accurate
assessment of the D-shaped mitral annulus.
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BACKGROUND Left atrial appendage (LAA) closure device sizing re-
quires accurate pre-procedural measurements. Presently, multi-
modality imaging with trans-esophageal echocardiography (TEE),
computed tomography angiography (CTA) and ﬂuoroscopy can be
utilized for this purpose. Correlation between measurements obtained
by all three modalities has not been adequately assessed.
METHODS Consecutive patients who underwent percutaneous LAA
closure [Amplatzer Cardiac Plug (ACP), Amulet, or WATCHMAN de-
vices] at Vancouver General Hospital who underwent routine CTA
pre-procedure were included in this analysis. Indications for LAA
closure were nonvalvular atrial ﬁbrillation patients at high stroke-risk
and contraindications for oral anticoagulation. Prospective cardiac-
gated CTAs were performed with Toshiba 320-detector or Siemens 2nd
generation 128-slice dual-source scanners, and images were inter-
preted with VitreaWorkstation. GFR <30mL/min/1.73m2 was an
exclusion for CTA. TEE was performed pre-procedure and largest
dimension used. Fluoroscopic measurements were performed with 5F
marker pigtails after transseptal puncture during LAA closure proce-
dure. All procedures were done under general anesthesia and TEE
guidance. LAA dimensions were obtained at (1) ACP landing zone at
10mm within the oriﬁce, (2) WATCHMAN anatomic oriﬁce, and (3)
WATCHMAN depth measurements. These measurements were
compared between CTA, TEE, and ﬂuoroscopy with Pearson (R) cor-
relation. Selection of device size was typically based upon the largest
oriﬁce dimension from any modality.
RESULTS Forty-one patients underwent CTA pre-LAA closure (8 ACP,
9 Amulet, 24 WATCHMAN). Average age was 74.9  8.8yrs, mean
CHADS2 score 2.9  1.3, and CHADS-VASc score 4.6  1.6. All had
contraindications to oral anticoagulation. Procedural success for de-
vice implantation was 100%. For ACP landing zone (deﬁned as 10mm
from LAA oriﬁce), all 3 modalities signiﬁcantly correlated with eachother: R value was 0.70 (p<0.00001) ﬂuoroscopy/TEE, 0.46 (p¼0.005)
ﬂuoroscopy/CTA, and 0.43 (p¼0.011) CTA/TEE. The mean landing
zone measurement was largest with CTA (23.6  4.2mm), followed by
TEE (21.9  5.3mm), and smallest with ﬂuoroscopy (19.8  5.3mm).
CONCLUSIONS All thee imaging modalities correlated with oriﬁce
landing zone measurements. CTA provided the largest measurements,
followed by TEE and ﬂuoroscopy.
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BACKGROUND Left atrial appendage (LAA) occlusion is gaining
increasing importance in clinical practice worldwide after having been
approved by the FDA as alternative to warfarin. Especially for the
Watchman device (Boston Scientiﬁc, Marlborough, MA, USA), the
measurement of the ostium size is a crucial step during implantation
and in many cases challenging, especially in ovally shaped ostia.
Choosing the wrong device size might lead to LAA perforations or
incomplete occlusions. Currently, ostium size is assessed by angiog-
raphy and transesophageal echocardiography (TEE, 0, 45, 90, 135).
We assessed whether the perimeter derived diameter (PDD) and area
derived diameter (ADD) as assessed by intraprocedural 3D TEE help to
standardize the process of choosing the device size even in ovally
shaped ostia.
METHODS 55 consecutive patients underwent LAA occlusion with the
Watchman device. The device size was chosen to yield a compres-
sion of 10-30% by angiography and 2D TEE. In addition, 3D TEE data
sets of the LAA ostium were obtained before and after implantation in
order to calculate PDD and ADD.
RESULTS The results for pre-interventional measured area, perim-
eter, PDD and ADD as compared with the pre-deﬁned target range of
10-30% compression are shown in Figure 1. The 3D measurements
correlate well with the calculated values for a 10-30% range of
compression.
CONCLUSIONS Measured PDD and ADD show a good correlation with
the implanted device sizes, especially the PDD correlates well with the
conventional 2D measurements. Therefore, we propose a standard-
ized algorithm for choosing the Watchman device sizes using 3D TEE
images as shown in Table 1, that can be adopted directly to clinical
practice. In comparison to the conventional 2D measurements this
algorithm simpliﬁes the sizing of the ostium and thereby possibly
further improves safety and efﬁcacy of the procedure.
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BACKGROUND Warfarin is commonly used for stroke risk reduction
in atrial ﬁbrillation (AF). While effective at reducing the risk of
ischemic stroke, it increases the risk of bleeding. Left atrial appendage
closure (LAAC) provides embolic protection and enables most patients
to discontinue lifelong oral anticoagulation (OAC). This analysis
sought to quantify the cost to the US Centers for Medicare & Medicaid
Services (CMS) of bleed-related complications with warfarin compared
to LAAC with the WATCHMAN.
METHODS A Markov model was developed to assess cost of bleeding
complications with LAAC versus warfarin from a CMS perspective over
a 20-year time horizon. Probabilities for major bleeding events were
determined from a pooled analysis of the PROTECT AF and PREVAIL
trials. For costing purposes, LAAC patients were assumed to adhere to
the OAC regimen in these study protocols. According to published
data, bleeding history and age were modeled to increase bleeding risk.
Bleed-related mortality risk was obtained from 2012 US HCUP data.
Costs of bleeds included direct costs due to in-patient care as well as
long-term disability costs. Cost data were taken from the literature
and 2015 US DRGs/CPTs.
RESULTS The procedural-related bleeding event rate with LAAC was
4.9%, with an average cost to CMS of $176 per patient. Modeled post-
procedural bleed event rates were 5.1% for LAAC compared to 11.5%
for warfarin. Hemorrhagic stroke accounted for 18% and 24% of these
bleed events for LAAC and warfarin, respectively. At 20 years, direct
costs for non-procedural bleeds were $3,111 per LAAC patient and
$9,244 per warfarin patient. On average, long-term disability costs
accounted for an additional $3,440 per LAAC patient and $10,502 per
warfarin patient. Total bleeding costs were $13,195 greater with
warfarin than LAAC.
CONCLUSIONS This analysis suggests that among AF patients at risk
for stroke, bleeding-related costs to CMS are nearly 3 times greater
with chronic warfarin compared to LAAC with WATCHMAN. This
should be considered when assessing the overall cost beneﬁt for non-
pharmacological, stroke risk reduction therapies in AF.
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BACKGROUND Outcome data comparing ischemic functional mitral
regurgitation (I-FMR) versus non-ischemic FMR (NI-FMR) following
percutaneous repair are not currently available in the literature. We
aimed to describe the early and 12-month results following MitraClip
device implantation regarding the two etiologies.
METHODS Between January 2011 December 2012 the Transcatheter Valve
Treatment Sentinel Pilot Registry included 452 patients with FMR who
underwent MitraClip procedure in 25 centers of 8 European countries.
RESULTS The prevalent etiology was I-FMR (235 patients, 52.0%). I-FMR
group had a signiﬁcant higher proportion of men (74.9 vs 59.9%, p<0.001)
and surgical risk (logistic EuroScore 24.818.2 vs 18.816.3, p<0.001).
Acute procedural success was high (95.8%) and similar between groups
(p¼0.48). Patients with I-FMR required a higher, albeit not signiﬁcant,
number of clips to reduce MR (p¼0.08). In-hospital mortality was low
(2.0%) without signiﬁcant differences between etiologies. Both I-FMR and
NI-FMR showed a signiﬁcant post-clip improvement in NYHA functional
class with the majority of patients exhibiting a NYHA class<II (82.6 and
74.2%, respectively). EuroSCORE,an impairedejection fraction (i.e.<30%),
pre-procedural chronic kidneydiseaseand the inability to reduce themitral
regurgitation represented the most important factors affecting both sur-
vival and re-hospitalization in FMR patients. Estimated overall 1-year
mortality and re-hospitalization rates were 15.0 and 25.8% respectively,
However, even though no signiﬁcant differences in terms of long-term
outcomeswere demonstrated, the survival curve showed a trend toward a
gradual decline in the I-FMR group versus a stabilization in the NI-FMR
group after 6 months. Paired echocardiographic data, available for 264
consecutive patients, showed a persistent improvement of MR at 1 year in
bothI-FMR and NI-FMR (6.6 and 5.4% of the patients with severe MR,
respectively). Despite a signiﬁcant overall reverse atrial remodeling after
clip, suggestive for an effective correction of the volume overload, no sig-
niﬁcate changes in left ventricular volumes have been demonstrated.
However, although both etiologies, showed a signiﬁcant acute decrease in
pulmonary pressure, only the I-FMR group demonstrated a concomitant
signiﬁcant acutedecrement inatrial volume (DLAV13.6ml,p¼0.016),while
at the 1-year follow-up a signiﬁcate reductionwas detected in both groups.
CONCLUSIONS This independent large cohort showed that percuta-
neous “edge-to-edge” therapy is associated with early and long-term
improvement of MR severity and functional status both in I-FMR and
NI-FMR groups. However some, albeit not signiﬁcant, differences
detectable both in the echocardiographic patterns and long-term
outcomes, suggest the possibility that the beneﬁt of Mitraclip differ
depending on the etiologies of mitral regurgitation prompting the
need for further large controlled studies investigating the underlying
pathogenetic mechanisms of FMR.
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